State of Alaska Department of Revenue Boosts Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

State of Alaska Department of Revenue increased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 144.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 131,751 shares of the life sciences company’s stock after buying an additional 77,825 shares during the quarter. State of Alaska Department of Revenue’s holdings in Integra LifeSciences were worth $2,393,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares during the period. CWM LLC boosted its position in shares of Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 425 shares during the period. Northwest Investment Counselors LLC bought a new position in shares of Integra LifeSciences in the third quarter valued at approximately $73,000. Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences in the second quarter valued at approximately $114,000. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 2.8 %

Shares of IART stock opened at $19.28 on Friday. The stock’s 50-day moving average price is $18.62 and its 200-day moving average price is $24.57. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of 66.48, a price-to-earnings-growth ratio of 0.66 and a beta of 1.09.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JMP Securities dropped their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Morgan Stanley lifted their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Bank of America dropped their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences has a consensus rating of “Hold” and an average price target of $26.50.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.